Navigation Links
Measles Deaths Worldwide Drop By Nearly 40% Over Five Years

The World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) today announced that countries are on target to halve deaths from measles, a leading vaccine-preventable killer, by the end of this year. Global measles deaths have plummeted by 39%, from 873 000 in 1999 to an estimated 530 000 in 2003.

The largest reduction occurred in Africa, the region with the highest burden of the disease, where estimated measles deaths decreased by 46%.

"Progress of this magnitude is remarkable. I congratulate countries for their successful efforts in protecting children from measles," said Dr LEE Jong-wook, WHO Director-General. "I am certain that with increased commitment from governments and further support from the international community, even more can be accomplished."

Measles is an important cause of childhood deaths. Only a decade ago, measles killed millions of children each year and affected 30 million more, leaving many with life-long disabilities like blindness and brain damage.

"In many places where families once lived in fear of losing their children to measles, they're now protected by an effective and inexpensive vaccine," said Carol Bellamy, Executive Director of UNICEF. "What clearer proof could there be of the value of investing in immunization?"

The dramatic decline in measles deaths is made possible through the commitment of governments to fully implement the WHO/UNICEF strategy for sustainable measles mortality reduction.

The strategy seeks to achieve routine measles immunization coverage of at least 90% in every district and to ensure that every child from nine months to 14 years of age receives a "second opportunity" for measles immunization through routine services or supplementary immunization activities (SIAs) every three to four years. The SIAs have proven especially effective. From 1999 to 2003, more than 350 million children throughout the world were vaccinated against measles through
'"/>

Source:WHO


Page: 1 2

Related biology news :

1. Mayo Clinic Researchers Create Obedient Virus; First Step To Use Measles Virus Against Cancer
2. New Estimates For The Causes Of Child Deaths Worldwide
3. Nearly half of people who need cholesterol treatment dont get it
4. A New Species of Monkey is Discovered in Tanzania: The First in Africa for More Than 20 Years
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Measles Deaths Worldwide Drop Nearly Over Five Years

(Date:5/29/2015)... May 28, 2015 Research and Markets ... the "Facial Recognition Market by Solution, by ... Forecast to 2020" report to their offering. ... facial recognition technology become more efficient and cost ... traction and investment from the commercial sector. The ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... contact the Communications and External Relations staff member identified at the ... research and development activities, please refer to one of our Media ... can send it to news@ornl.gov . ... recovering from injuries, the elderly and even athletes could one day ...
... CHAMPAIGN, lll. A protein that helps pack DNA into ... activity, scientists report. The researchers found that the protein, histone ... cellular workbenches on which all proteins are made. The ... Cell Biology . A human cell,s genetic material is ...
... occurrence of fishes in the ocean,s deepest reachesthe hadal zone, ... are more numerous at such depths than experts had thought. ... July/August issue of BioScience , observed 10 to 20 ... baited video lander in the Japan Trench. The observation period ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory July 2010 2Story tips from the Department of Energy's Oak Ridge National Laboratory July 2010 3Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3Study suggests more fish than thought may thrive in the ocean's depths 2
(Date:5/30/2015)... May 30, 2015 The Cholangiocarcinoma ... research for bile duct cancer, announced today the ... Fellowship Program. , The Foundation has ... throughout the country to raise awareness about cholangiocarcinoma ... support research that opens new pathways for diagnosis ...
(Date:5/30/2015)... 2015 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... BAX ) today announced data from PERSIST-1 – ... the treatment of myelofibrosis – in a late-breaking oral ... American Society of Clinical Oncology (ASCO), May 29-June 2, ... is an investigational oral multikinase inhibitor with specificity for ...
(Date:5/30/2015)... and RARITAN, N.J. , ... multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) ... investigational, human anti-CD38 monoclonal antibody – achieved an ... CI, 20.8-38.9), as assessed by an independent review ... The ORR was consistent among the pre-specified subgroups ...
(Date:5/30/2015)... May 30, 2015  Caris Life Sciences® today ... in which researchers identified biomarker changes, including key ... tumors, indicating changes in response to therapy as ... was a subset of a larger study analyzing ... the cancer. These data utilizing Caris Molecular Intelligence®, ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... 2009 Waukesha Electric Systems, SuperPower, University of Houston, Oak ... in a $10.7 million smart grid demonstration project award ... on November 24. The funds will be used to ... the reliability of the nation,s power grid. , ...
... 22 /PRNewswire/ - Viron Therapeutics Inc., a biotechnology company ... that it has been granted U.S. patents related to ... These patents join a portfolio of more than 80 ... drug discovery platform identifies proteins expressed by non-human viruses ...
... , , , , SEATTLE, Dec. 22 ... announced today its support of the Pharmaceutical Research Manufacturers ... revised July 2008" (PhRMA Code). Adherence to the ... , "As CTI prepares for the potential launch ...
Cached Biology Technology:Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 2Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 3Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates 2Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates 3Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals 2Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals 3Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals 4
... Rotor for use in the ... and Centra-MP4/MP4R. Perfect for ... and other difficult to separate ... containment. Complete with rotor and ...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Buckets for tube holder inserts...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
Biology Products: